Abeona Therapeutics Inc. Q3 2026 Earnings Call Summary Moby Intelligence Mon, November 9, 2026 at 4:44 PM EST 4 min read NVDA -3.91% ABEO -39.10% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management attributes the 18% quarter-over-quarter ZEVASKYN revenue growth to a maturing launch infrastructure and the expansion of the Qualified Treatment Center (QTC) network to eight active sites.
The acquisition of ABO-801 (formerly APT-1011) is intended to transform Abeona into a diversified, revenue-generating company by adding a Phase III-ready orphan drug with a peak annual revenue potential exceeding $750 million.
Management noted that newer QTCs are advancing patients through prior authorization and financial clearance faster than initial sites, reflecting the benefit of sharing best practices across the network.
The strategic rationale for ABO-801 centers on addressing the 'dearth of effective, safe, and convenient oral therapies' in an Eosinophilic Esophagitis (EoE) market currently dominated by injectable biologics.
A single ZEVASKYN batch was deemed out-of-specification for the pan-CK identity assay in Q3; while safety and efficacy were unaffected, the company could not recognize revenue for that specific treatment.
The company is leveraging its existing late-stage clinical and regulatory expertise to advance ABO-801 without distracting the commercial and manufacturing teams focused on the ZEVASKYN launch.
A planned annual manufacturing shutdown from mid-November to mid-January is expected to cause variable treatment timing, potentially pushing some late-2026 biopsy slots into early 2027.
Management anticipates initiating the ABO-801 Phase III study in mid-2027 following a Type C meeting with the FDA, with top-line results targeted for the end of 2028.
Manufacturing capacity for ZEVASKYN is on track to expand to 10 slots per month by mid-2027, pending the submission of process data to the FDA.
Long-term gross margins are projected to reach the 85% to 90% range as manufacturing volume increases and fixed costs are better utilized.
The company expects to enter 2027 with a significantly strengthened commercial foundation, including payer coverage for over 95% of commercial lives and established Medicaid coverage across all 50 states.
The ABO-801 acquisition was structured with $20 million in common stock upfront, plus $60 million in potential regulatory and commercial milestones and tiered royalties.
A $30 million private placement (PIPE) was completed alongside the acquisition to bolster the balance sheet for pipeline development and ZEVASKYN scaling.
The FDA approval of FAYUVI for Ultragenyx makes Abeona eligible for commercial milestones and royalties, stemming from a 2022 out-licensing agreement.
Management explicitly flagged that out-of-specification batches, while infrequent, require a single-patient IND process and prevent standard commercial billing.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Management will replace the proprietary PROSE tool used in previous failed trials with the industry-standard Dysphagia Symptom Questionnaire (DSQ) to reduce background noise.
The new study will focus on a 12-week co-primary endpoint to minimize the confounding effects of patient diet modification over longer periods.
The trial is powered at 90% with 400 patients to detect a projected 13% responder rate delta over placebo.
Abeona has achieved a high success rate of 14 out of 15 batches treated since launch, which management noted is favorable for autologous cell therapies.
In cases of out-of-specification results that do not impact safety, the company utilizes a single-patient IND to ensure the patient still receives the benefit of the therapy.
ABO-801 is positioned as a 'step-in' therapy to be used before patients move to injectable biologics like Dupixent.
The once-daily oral disintegrating tablet (ODT) formulation is designed to dissolve in 30 seconds at bedtime, offering a convenience advantage over existing oral slurries.
A dedicated team is working on maximizing cell yield from biopsies to increase the number of sheets delivered per patient.
Current clean room space can support up to 10 manufacturing slots per month; expansion beyond that would require additional construction.
